Why This U.S. Auto Retail Stock is Barclays’ Top Pick Right Now

RB Global reported Q2 2026 results on an earnings call. Gross Transaction Value rose 11% to $4.7B, total revenue rose 11% to $1.3B, and non-GAAP diluted EPS rose 6% to $1.13. Adjusted EBITDA increased 6% to $387.2M. The company raised 2026 GTV guidance to 9% to 11% and adjusted EBITDA guidance to $1.495B to $1.545B, citing growth and BigIron integration.

RB Global (NYSE:RBA) reported Q2 call highlights on integration of BigIron and segment performance. Management said BigIron’s financial impact will be reflected later in the year. Automotive GTV rose 13% and heavy equipment/transportation GTV rose 8%. Service revenue grew 5% with take rate down 110 bps to 20%. Full-year 2026 GTV guidance raised to 9% to 11%, with adjusted EBITDA growth ~8.6% midpoint; dividend increased and CAD 150M buyback reported.

RB Global, Inc. (RBA, RBA.TO) reported higher second-quarter net income, attributing the increase to higher revenue. The company also raised its FY2026 guidance, lifting the expected growth outlook to 9% to 11% for GTV, with BigIron adding about $500 million in GTV, according to the report.

RB Global (NYSE:RBA) reported Q2 CY2026 revenue of $1.32 billion, up 11.1% year on year, exceeding Wall Street estimates by 6.8%. Non-GAAP adjusted EPS was $1.13, up from $1.07, and was roughly in line with consensus. Analysts expect full-year EPS to rise from $4.18 to $4.64.

Guardant Health was ordered to pay $245.2m to TwinStrand Biosciences and the University of Washington for patent infringement. The ruling covers 11 products, including Guardant360 CDx, and includes damages, royalties, and interest. Guardant plans to appeal, while TwinStrand affirms its commitment to its intellectual property.

Kura Oncology's stock rose 11.6% in pre-market trading after CEO Troy Wilson bought 100,000 shares for $1.24 million, his second large purchase in a week. Analysts Citigroup and Jefferies reaffirmed positive ratings, citing strong commercial momentum for KOMZIFTI and Q2 earnings beat. The stock surpassed its 52-week high of $12.90.